Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Early identification of high-risk pregnancies using single-cell mass cytometry
FY 2023-24
Summary
Preeclampsia (PE) is a hypertensive placental syndrome affecting 5-8% of pregnancies globally. In its more severe (sPE) forms it is responsible for >70,000 maternal and 500,000 perinatal deaths annually. Thus, there is a pressing need for effective interventions to avert this disease and promote safe maintenance of pregnancy towards term. The critical needs in mitigating the threats from PE centre on the precise identification of patients at risk of developing this condition in a crucial window where placental dysfunction may be avoided during early pregnancy. With this goal in mind, we have identified a promising link between 1st trimester protein expression signatures in placenta-derived extra-villous trophoblast cells that are released into the cervical canal (cEVT) and subsequent maternal circulating biomarkers, placental and fetal sonography, and clinicopathological evidence at birth of the underlying placental diseases that cause sPE. With use of single-cell mass cytometry (CyTOF), non-invasively collected cEVT samples can be analyzed for biomarkers that identify the pregnancy as low or high-risk of developing sPE. By leveraging the precision of CyTOF and advancements of machine-learning pipelines, we intend to maximize our understanding of the molecular pathology of sPE as the disease is evolving in-vivo. 500 patients in the 1st trimester will be enrolled from Mount Sinai and Sunnybrook Health Sciences Centre, their cEVT and blood samples taken during standard visits to aid the baseline characterization of low-risk cEVT profiles and to determine the capability of cEVT-derived prognoses for high-risk pregnancies.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506373
Name
Lee Mavis
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Early identification of high-risk pregnancies using single-cell mass cytometry
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
1st Trimester; Antibody Validation; Cervical Extra-Villous Trophoblast; Cytometry By Time-Of-Flight; Early Assessment; Flow Cytommetry; Machine Learning; Protein Biomarkers; Severe Preeclampsia; Single-Cell Mass Cytometry
Abstract
Preeclampsia (PE) is a hypertensive placental syndrome affecting 5-8% of pregnancies globally. In its more severe (sPE) forms it is responsible for >70,000 maternal and 500,000 perinatal deaths annually. Thus, there is a pressing need for effective interventions to avert this disease and promote safe maintenance of pregnancy towards term. The critical needs in mitigating the threats from PE centre on the precise identification of patients at risk of developing this condition in a crucial window where placental dysfunction may be avoided during early pregnancy. With this goal in mind, we have identified a promising link between 1st trimester protein expression signatures in placenta-derived extra-villous trophoblast cells that are released into the cervical canal (cEVT) and subsequent maternal circulating biomarkers, placental and fetal sonography, and clinicopathological evidence at birth of the underlying placental diseases that cause sPE. With use of single-cell mass cytometry (CyTOF), non-invasively collected cEVT samples can be analyzed for biomarkers that identify the pregnancy as low or high-risk of developing sPE. By leveraging the precision of CyTOF and advancements of machine-learning pipelines, we intend to maximize our understanding of the molecular pathology of sPE as the disease is evolving in-vivo. 500 patients in the 1st trimester will be enrolled from Mount Sinai and Sunnybrook Health Sciences Centre, their cEVT and blood samples taken during standard visits to aid the baseline characterization of low-risk cEVT profiles and to determine the capability of cEVT-derived prognoses for high-risk pregnancies.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lee, Mavis
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~